L Robson
- Molecular Biology
- Oncology top 5%
- Biomaterials top 10%
- Pulmonary and Respiratory Medicine
- Biomedical Engineering
- Co-authors
- Alan V. BoddyDavid R. NewellMark R. MiddletonRuth PlummerChristopher J. JonesJeffrey EvansHeidi SteinfeldtAnna L Olsen
- Topics
- Cancer Treatment and Pharmacology (5 papers)Cancer therapeutics and mechanisms (5 papers)Ovarian cancer diagnosis and treatment (4 papers)
- Partner nations
- United KingdomSouth AfricaItaly
In The Last Decade
L Robson
21 papers receiving 859 citations
Peers
Comparison fields: 5 of 89
- Molecular Biology 503
- Oncology 486
- Biomaterials 122
- Pulmonary and Respiratory Medicine 84
- Biomedical Engineering 75
Countries citing papers authored by L Robson
This map shows the geographic impact of L Robson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Robson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Robson more than expected).
Fields of papers citing papers by L Robson
This network shows the impact of papers produced by L Robson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Robson. The network helps show where L Robson may publish in the future.
Co-authorship network of co-authors of L Robson
This figure shows the co-authorship network connecting the top 25 collaborators of L Robson. A scholar is included among the top collaborators of L Robson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Robson. L Robson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 42 | |
| 2 | 26 | |
| 3 | 66 | |
| 4 | 298 | |
| 5 | A novel human enzyme with a bis-chloro-phenol prodrug for Antibody Directed Enzyme Prodrug Therapy (ADEPT) | 2 |
| 6 | Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours. | 0 |
| 7 | 10 | |
| 8 | AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients | 3 |
| 9 | 18 | |
| 10 | Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide | 6 |
| 11 | 84 | |
| 12 | 37 | |
| 13 | 92 | |
| 14 | 33 | |
| 15 | Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors | 6 |
| 16 | Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. | 17 |
| 17 | 37 | |
| 18 | 45 | |
| 19 | 11 | |
| 20 | 1 |
About L Robson
L Robson is a scholar working on Oncology, Reproductive Medicine and Toxicology, having authored 22 papers that have together received 889 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (5 papers) and Ovarian cancer diagnosis and treatment (4 papers). The work is most often cited by research in Oncology (486 citations), Biomaterials (122 citations) and Molecular Biology (503 citations). L Robson has collaborated with scholars based in United Kingdom, South Africa and Italy. Frequent co-authors include Alan V. Boddy, David R. Newell, Mark R. Middleton, Ruth Plummer, Christopher J. Jones, Jeffrey Evans, Heidi Steinfeldt, Anna L Olsen, Hilary Calvert and Richard H. Wilson. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.